Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis
| Autor: | Hien T. Trinh, Richard A. Bowen, Jeffrey A. Frelinger, Daniel A. Powell, Stephanie M. Porter, Airn E. Hartwig, Edward J Robb, Angela M. Bosco-Lauth, Marc J. Orbach, James Hoskinson, Helle Bielefeldt-Ohmann, John N. Galgiani, Hilary Moale, Lisa F. Shubitz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Disease
Vaccines Attenuated Dogs Pulmonary coccidioidomycosis Medicine Animals Lung Coccidioidomycosis General Veterinary General Immunology and Microbiology biology business.industry Vaccination Public Health Environmental and Occupational Health Spores Fungal biology.organism_classification Coccidioides posadasii Infectious Diseases medicine.anatomical_structure Tolerability Immunology Molecular Medicine Arthroconidium Lymph Fungal Vaccines business |
| Zdroj: | Vaccine. 39(47) |
| ISSN: | 1873-2518 |
| Popis: | Coccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Δcps1, was tested for tolerability and efficacy to prevent pulmonary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but disease scores were not significantly different from unvaccinated (P = 0.675). Δcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Δcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect